113 related articles for article (PubMed ID: 37006072)
21. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
22. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.
Spinola M; Leoni VP; Tanuma J; Pettinicchio A; Frattini M; Signoroni S; Agresti R; Giovanazzi R; Pilotti S; Bertario L; Ravagnani F; Dragani TA
Oncol Rep; 2005 Aug; 14(2):415-9. PubMed ID: 16012724
[TBL] [Abstract][Full Text] [Related]
23. Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development.
Naidu R; Har YC; Taib NA
Oncol Res; 2009; 18(2-3):65-71. PubMed ID: 20066896
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
[TBL] [Abstract][Full Text] [Related]
25.
Akdeniz Odemis D; Tuncer SB; Adamnejad Ghafour A; Jabbarli K; Gider Y; Celik B; Kuru Turkcan G; Sukruoglu Erdogan O; Kilic Erciyas S; Avsar M; Kebudi R; Buyukkapu Bay S; Tuncer S; Yazici H
J Oncol; 2020; 2020():9401038. PubMed ID: 33456465
[TBL] [Abstract][Full Text] [Related]
26. Association between fibroblast growth factor receptor 4 Gly388Arg polymorphism and ischaemic stroke.
Zhang HF; Zhao KJ; Yang PF; Fang YB; Zhang YH; Liu JM; Huang QH
J Int Med Res; 2012; 40(5):1708-14. PubMed ID: 23206452
[TBL] [Abstract][Full Text] [Related]
27. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
da Costa Andrade VC; Parise O; Hors CP; de Melo Martins PC; Silva AP; Garicochea B
Exp Mol Pathol; 2007 Feb; 82(1):53-7. PubMed ID: 17084840
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
Quintanal-Villalonga Á; Carranza-Carranza A; Meléndez R; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Lung Cancer; 2017 Nov; 18(6):667-674.e1. PubMed ID: 28583379
[TBL] [Abstract][Full Text] [Related]
29. The Gly385(388)Arg Polymorphism of the FGFR4 Receptor Regulates Hepatic Lipogenesis Under Healthy Diet.
Lutz SZ; Hennige AM; Peter A; Kovarova M; Totsikas C; Machann J; Kröber SM; Sperl B; Schleicher E; Schick F; Heni M; Ullrich A; Häring HU; Stefan N
J Clin Endocrinol Metab; 2019 Jun; 104(6):2041-2053. PubMed ID: 30541128
[TBL] [Abstract][Full Text] [Related]
30. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.
Spinola M; Leoni V; Pignatiello C; Conti B; Ravagnani F; Pastorino U; Dragani TA
J Clin Oncol; 2005 Oct; 23(29):7307-11. PubMed ID: 16061909
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor 4 Gly388Arg polymorphism associated with severity of gallstone disease in a Chinese population.
Chen Q; Li WJ; Wan YY; Yu CD; Li WG
Genet Mol Res; 2012 Mar; 11(1):548-55. PubMed ID: 22535390
[TBL] [Abstract][Full Text] [Related]
32.
Kim JH; Jeong SY; Jang HJ; Park ST; Kim HS
Front Oncol; 2021; 11():762528. PubMed ID: 34737965
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma.
Cha Z; Zang Y; Guo H; Gu H; Tu X; Song H; Qian B
Mol Biol Rep; 2014 Feb; 41(2):1165-70. PubMed ID: 24381107
[TBL] [Abstract][Full Text] [Related]
34. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
35. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
Matakidou A; El Galta R; Rudd MF; Webb EL; Bridle H; Eisen T; Houlston RS
Br J Cancer; 2007 Jun; 96(12):1904-7. PubMed ID: 17519899
[TBL] [Abstract][Full Text] [Related]
36. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
37. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma.
Gao L; Feng Z; Li Q; Li L; Chen L; Xiao T
Tumour Biol; 2014 Apr; 35(4):2997-3002. PubMed ID: 24248544
[TBL] [Abstract][Full Text] [Related]
39. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.
Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
[TBL] [Abstract][Full Text] [Related]
40. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
